2C-N

Use and effects

In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists 2C-N's dose range as 100 to 150mg or more orally and a duration of 4 to 6hours. It has an estimated typical dose of about 120mg orally. Its onset is within 30minutes and peak effects occur after 1hour. The effects of 2C-N have been reported to include some visual changes, similarities to MDMA, lightheadedness, eye wiggling, easier conversation, and improved mood. It was described as a "strange material, but okay".

Interactions

2C drugs like 2C-N are known to be metabolized by the monoamine oxidase (MAO) enzymes MAO-A and MAO-B. Monoamine oxidase inhibitors (MAOIs) such as phenelzine, tranylcypromine, moclobemide, and selegiline may potentiate the effects of 2C drugs like 2C-N. This may result in overdose and serious toxicity.

Pharmacology

Pharmacodynamics

2C-N is a low-potency partial agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors.

Chemistry

Properties

Salts of 2C-N have a bright yellow to orange color due to the presence of the nitro group, unlike all other members of the 2C family in which the salts are white.

Synthesis

The chemical synthesis of 2C-N has been described. It is synthesized by the mixed acid nitration of 2C-H using sulfuric acid and nitric acid.

Analogues

Analogues of 2C-N include DON, 2C-CN, and 25N-NBOMe, among others.

History

2C-N was first described in the scientific literature by at least 1991.

Society and culture

Legal status

Canada

As of October 31, 2016, 2C-N is a controlled substance (Schedule III) in Canada.

United Kingdom

2C-N and most (possibly all) other compounds featured in PiHKAL are illegal drugs in the United Kingdom.

United States

In the United States, 2C-N is a Schedule 1 controlled substance.

References

References

1. {{CitePiHKAL [http://www.erowid.org/library/books_online/pihkal/pihkal034.shtml 2C-N Entry in ''PiHKAL'']
2. (October 2018). "Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics". Int J Neuropsychopharmacol.
3. (June 2013). "2C or not 2C: phenethylamine designer drug review". J Med Toxicol.
4. (January 2007). "Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series)". Biochem Pharmacol.
5. (January 2024). "Drug-drug interactions involving classic psychedelics: A systematic review". J Psychopharmacol.
6. (10 May 2025). "Kᵢ Database".
7. (December 2015). "Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)". Neuropharmacology.
8. (December 2023). "Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential". Nat Commun.
9. (June 2007). "Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors". J Pharmacol Exp Ther.
10. (February 2019). "Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases". Drug Test Anal.
11. (April 2016). "In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1". J Pharmacol Exp Ther.
12. (June 2002). "Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT(2A) and 5-HT(2C) receptors". Br J Pharmacol.
13. (August 2023). "Structure-Activity Assessment and In-Depth Analysis of Biased Agonism in a Set of Phenylalkylamine 5-HT2A Receptor Agonists". ACS Chem Neurosci.
14. (4 May 2016). "Canada Gazette – Regulations Amending the Food and Drug Regulations (Part J — 2C-phenethylamines)".
15. (April 2022). "Lists of: Scheduling Actions, Controlled Substances, Regulated Chemicals". Drug Enforcement Administration.